Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Assessment of sorafenib induced changes in tumor perfusion of uveal melanoma metastases with dynamic contrast-enhanced ultrasound (DCE-US)In: Journal of Cancer Research and Clinical Oncology Jg. 148 (2022) S. 955 - 965ISSN: 1432-1335; 0171-5216; 0084-5353; 0301-1585Online Volltext: dx.doi.org/ (Open Access)
-
Improved survival in metastatic breast cancer : results from a 20-year study involving 1033 women treated at a single comprehensive cancer centerIn: Journal of Cancer Research and Clinical Oncology (2020)ISSN: 1432-1335; 0171-5216; 0084-5353; 0301-1585Online Volltext: dx.doi.org/ (Open Access)
-
STREAM : A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (5) treatment of chemonaive patients (pts) with metastatic uveal melanoma (MUM)In: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 15, S. 9511ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumorsIn: Cancer Chemotherapy and Pharmacology Jg. 78 (2016) Nr. 2, S. 405 - 417ISSN: 0344-5704; 1432-0843Online Volltext: dx.doi.org/ (Open Access)
-
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER studyIn: Journal of Hepatology Jg. 65 (2016) Nr. 2, S. 280 - 288ISSN: 0168-8278Online Volltext: dx.doi.org/
-
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer : a study of the CESAR Central European Society for Anticancer Drug Research-EWIVIn: European journal of cancer Jg. 51 (2015) Nr. 1, S. 27 - 36ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/
-
Clinical benefit and health-related quality of life assessment in patients treated with cisplatin/S-1 versus cisplatin/5-FU : secondary end point results from the first-line advanced gastric cancer study (FLAGS)In: Journal of gastrointestinal cancer Jg. 46 (2015) Nr. 2, S. 109 - 117ISSN: 1941-6628; 1941-6636Online Volltext: dx.doi.org/
-
Overcoming the proliferation rate paradox : Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 2528ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ Online Volltext
-
Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumoursIn: European journal of cancer Jg. 51 (2015) Nr. 2, S. 146 - 156ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/
-
A preliminary population pharmacokinetic model for doese selection of treosulfan used in conditioning treatment prior to haematopoietic stem cell transplantation (HSCT) in childrenIn: Bone Marrow Transplantation Jg. 49 (2014) Nr. Suppl. 1, S. S360 - S361ISSN: 1476-5365; 0268-3369Online Volltext: dx.doi.org/
-
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreasIn: European Journal of Cancer Jg. 50 (2014) Nr. 12, S. 2072 - 2081ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging dataIn: International Journal of Clinical Pharmacology and Therapeutics Jg. 52 (2014) Nr. 8, S. 642 - 652ISSN: 0946-1965Online Volltext: dx.doi.org/
-
First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle proteinIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 2564ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021) : A multicentric randomized trialIn: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 742 - 746ISSN: 1569-8041Online Volltext: dx.doi.org/
-
Phase i study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsIn: British Journal of Cancer (BJC) Jg. 110 (2014) Nr. 5, S. 1155 - 1162ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access)
-
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumorsIn: Cancer Chemotherapy and Pharmacology: CPP Jg. 71 (2013) Nr. 1, S. 93 - 101ISSN: 1432-0843; 0344-5704; 0943-9404Online Volltext: dx.doi.org/
-
A Phase i dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancerIn: Breast Cancer Research and Treatment Jg. 140 (2013) Nr. 2, S. 331 - 339ISSN: 1573-7217; 0167-6806Online Volltext: dx.doi.org/
-
A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With DocetaxelIn: Journal of Cardiovascular Pharmacology Jg. 61 (2013) Nr. 6, S. 495 - 504ISSN: 1533-4023; 0160-2446Online Volltext: dx.doi.org/
-
A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreasIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) S. 291 - 291ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil : A Randomized, Two-Period Crossover Study in Patients With Advanced CancerIn: Clinical Therapeutics Jg. 35 (2013) Nr. 12, S. 1946 - 1954ISSN: 1879-114X; 0149-2918Online Volltext: dx.doi.org/
-
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agentsIn: Graefe's Archive for Clinical and Experimental Ophthalmology Jg. 251 (2013) Nr. 1, S. 279 - 284ISSN: 0721-832X; 1435-702XOnline Volltext: dx.doi.org/
-
First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumorsIn: PLoS ONE Jg. 8 (2013) Nr. 12, S. e83232ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Breast Cancer Research and Treatment Jg. 142 (2013) Nr. 1, S. 81 - 88ISSN: 1573-7217; 0167-6806Online Volltext: dx.doi.org/
-
Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer : A study of the CESAR Central European Society for Anticancer Drug Research-EWIVIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. 4035ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Resminostat in advanced hepatocellular carcinoma (HCC) : Overall survival subgroup analysis of prognostic factors in the SHELTER trialIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. e15088ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanomaIn: Cancer Medicine Jg. 2 (2013) Nr. 2, S. 208 - 215ISSN: 2045-7634Online Volltext: dx.doi.org/
-
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-nave patients with unresectable exocrine adenocarcinoma of the pancreas-a study within the Central European Society Anticancer Drug Research (CESAR) collaborative networkIn: British Journal of Cancer (BJC) Jg. 107 (2012) Nr. 2, S. 280 - 286ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access)
-
An investigator-initiated monocentric phase I dose escalation trial of temsirolimus and irinotecan (TEMIR) in patients with relapsing glioblastoma multiforme (reGBM)In: Journal of Clinical Oncology Jg. 30 (2012) Nr. Suppl. 15, S. 2086ISSN: 0732-183X; 1527-7755
-
Antitumoral Activity of a New Class of TriazenesIn: European Journal of Cancer Jg. 48 (2012) Nr. Suppl. 6, S. 27 - 28ISSN: 0959-8049
-
Chemosensitivity of conjunctival melanoma cell lines to single chemotherapeutic agents and combinationsIn: British Journal of Ophthalmology (BJO) Jg. 96 (2012) Nr. 4, S. 591 - 596ISSN: 1468-2079; 0007-1161Online Volltext: dx.doi.org/
-
Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumorsIn: Cancer Chemotherapy and Pharmacology Jg. 69 (2012) Nr. 3, S. 753 - 761ISSN: 0344-5704; 1432-0843Online Volltext: dx.doi.org/
-
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumorsIn: Clinical Cancer Research Jg. 18 (2012) Nr. 17, S. 4794 - 4805ISSN: 1078-0432; 1557-3265Online Volltext: dx.doi.org/ (Open Access)
-
Phase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST)In: Journal of Clinical Oncology Jg. 30 (2012) Nr. Suppl. 15, S. 10032ISSN: 0732-183X; 1527-7755
-
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancerIn: Investigational New Drugs: The Journal of New Anticancer Agents Jg. 30 (2012) Nr. 3, S. 1138 - 1143ISSN: 0167-6997; 1573-0646Online Volltext: dx.doi.org/
-
Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma : Final results of the EORTC 18021 studyIn: Journal of Clinical Oncology Jg. 30 (2012) Nr. Suppl. 15, S. 8532ISSN: 0732-183X; 1527-7755
-
Regorafenib (BAY 73-4506) in advanced colorectal cancer : a phase I studyIn: British Journal of Cancer (BJC) Jg. 106 (2012) Nr. 11, S. 1722 - 1727ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access)
-
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function : SHARP trial subanalysesIn: Journal of Hepatology Jg. 56 (2012) Nr. 5, S. 1080 - 1088ISSN: 0168-8278; 1600-0641Online Volltext: dx.doi.org/
-
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)In: Investigational New Drugs: The Journal of New Anticancer Agents Jg. 30 (2012) Nr. 3, S. 1184 - 1192ISSN: 0167-6997; 1573-0646Online Volltext: dx.doi.org/
-
A clinical phase I study evaluating tolerability and pharmacokinetics (PK) of TriN 2755 in patients (pts) with advanced solid tumors : A study in cooperation with the Central European Society for Anticancer Drug Research (CESAR-EWIV)In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 109 - 110ISSN: 0378-584X; 1423-0240
-
A phase I study evaluating the pharmacokinetics of components of S-1 in pts with varying degrees of renal functionIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. e13089ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatmentIn: International Journal of Clinical Pharmacology and Therapeutics Jg. 49 (2011) Nr. 1, S. 96 - 98ISSN: 0946-1965Online Volltext: dx.doi.org/
-
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patientsIn: International Journal of Clinical Pharmacology and Therapeutics Jg. 49 (2011) Nr. 1, S. 88 - 90ISSN: 0946-1965
-
Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agentsIn: International Journal of Clinical Pharmacology and Therapeutics Jg. 49 (2011) Nr. 1, S. 78 - 80ISSN: 0946-1965
-
Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer : Results of a phase I studyIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 1092ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumorIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 3017ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Phase I study of telatinib (BAY 57-9352) : analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancerIn: Vascular Cell Jg. 3 (2011) S. 16ISSN: 2045-824XOnline Volltext: dx.doi.org/
-
Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel)In: European Journal of Cancer Jg. 47 (2011) Nr. Suppl. 4, S. S30ISSN: 0959-8049Online Volltext: dx.doi.org/
-
Toll-like receptor 9 agonists as cancer therapeuticsIn: Expert Opinion on Investigational Drugs Jg. 20 (2011) Nr. 3, S. 361 - 372ISSN: 1744-7658Online Volltext: dx.doi.org/
-
Transarterial hepatic chemoperfusion of uveal melanoma metastases : Survival and response to treatmentIn: RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der Bildgebenden Verfahren Jg. 183 (2011) Nr. 12, S. 1151 - 1160ISSN: 0367-2239; 1438-9010Online Volltext: dx.doi.org/
-
10 Years CESAR Anticancer Drug Research : The 7th CESAR Annual Meeting 2009. PrefaceIn: International Journal of Clinical Pharmacology and Therapeutics Jg. 48 (2010) Nr. 7, S. 435 - 439ISSN: 0946-1965Online Volltext: dx.doi.org/
-
46 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - clinical efficacy and immunological results of a phase I studyIn: European Journal of Cancer / EJC Supplements Jg. 8 (2010) Nr. 7, S. 23 - 24ISSN: 1878-1217; 1359-6349Online Volltext: dx.doi.org/ (Open Access)
-
47 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - safety results of a clinical phase I studyIn: European Journal of Cancer / EJC Supplements Jg. 8 (2010) Nr. 7, S. 24ISSN: 1878-1217; 1359-6349Online Volltext: dx.doi.org/ (Open Access)
-
496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumoursIn: European Journal of Cancer / EJC Supplements Jg. 8 (2010) Nr. 7, S. 158 - 159ISSN: 1878-1217; 1359-6349Online Volltext: dx.doi.org/ (Open Access)
-
50 A phase I study of the safety, tolerability and pharmacokinetics of pazopanib (P) in combination with gemcitabine (G) for advanced solid tumorsIn: European Journal of Cancer / EJC Supplements Jg. 8 (2010) Nr. 7, S. 25ISSN: 1878-1217; 1359-6349Online Volltext: dx.doi.org/ (Open Access)
-
A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumorsIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. Suppl. 15, S. e13065ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Abstract P2-16-10: Combination of Tivozanib, an Oral Inhibitor of VEGFR, with Weekly Paclitaxel for Metastatic Breast Cancer : Preliminary Results of an Ongoing Phase 1 StudyIn: Cancer Research Jg. 70 (2010) Nr. 24, S. P2 - 16ISSN: 1538-7445; 0008-5472Online Volltext: dx.doi.org/
-
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancerIn: Annals of Oncology Jg. 21 (2010) Nr. 2, S. 275 - 282ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/
-
Chemosensitivity of conjunctival melanoma cell lines
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 66ISSN: 0378-584X; 1423-0240; 2296-5262; 2296-5270Online Volltext: dx.doi.org/ -
First-line treatment of patients with metastatic pancreatic cancer : Results of a Phase II trial with S-1 (CESAR-Study group)In: International Journal of Clinical Pharmacology and Therapeutics Jg. 48 (2010) Nr. 7, S. 470 - 472ISSN: 0946-1965Online Volltext: dx.doi.org/
-
Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancerIn: International Journal of Clinical Pharmacology and Therapeutics Jg. 48 (2010) Nr. 7, S. 473 - 475ISSN: 0946-1965Online Volltext: dx.doi.org/
-
Lack of neuroprotection by an ACTH (4-9) analogue : A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphomaIn: Journal of Cancer Research and Clinical Oncology Jg. 130 (2004) Nr. 3, S. 153 - 160ISSN: 1432-1335; 0171-5216; 0084-5353; 0301-1585Online Volltext: dx.doi.org/
-
Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantationIn: Bone Marrow Transplantation Jg. 31 (2003) Nr. 6, S. 487 - 491ISSN: 1476-5365; 0268-3369Online Volltext: dx.doi.org/ (Open Access)
-
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1: 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 19ISSN: 2296-5262Online Volltext: dx.doi.org/ (Open Access)
-
Systemic treatment of metastatic uveal melanoma - a silver lining on the horizon?
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 118 - 119ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ -
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastastic breast cancer patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Oncology Research and Treatment Jg. 36 (2013) Nr. Suppl. 7, S. 157ISSN: 0378-584X; 1423-0240Online Volltext: dx.doi.org/ -
A phase I dose-escalation study with pharmacokinetics (PK) of TriN 2755 in patients with advanced solid tumors : A study in cooperation with the Central European Society for Anticancer Drug Research (CESAR-EWIV)In: Cancer Research Jg. 71 (2011) Nr. 8, Suppl., S. 1293ISSN: 1538-7445; 0008-5472Online Volltext: dx.doi.org/
-
Clinical update on the phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC) - The Shelter Study
13th World Congress on Gastrointestinal Cancer 22–25 June 2011, Barcelona, Spain,In: Annals of Oncology Jg. 22 (2011) Nr. Suppl. 5, S. v76 - v76ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ -
A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumorsIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. 15 Suppl., S. 3011ISSN: 0732-183X; 1527-7755
-
Detection of new hepatic metastases in computed tomography (CT) with hepatic metastatic choroidal melanoma in Antiangiogenic Therapy - Progress or Pseudoprogression?
29. Deutscher Krebskongress. Berlin 24.-27. Februar 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 2, S. 188ISSN: 0378-584X; 1423-0240; 2296-5270; 2296-5262Online Volltext: dx.doi.org/ -
Evaluation of lesions density in computed tomography (CT) for assessment of tumor response in patients with hepatic metastatic choroidal melanoma under therapy with sorafenib
29. Deutscher Krebskongress. Berlin 24.-27. Februar 2010,In: Oncology Research and Treatment Jg. 33 (2010) Nr. Suppl. 2, S. 182ISSN: 0378-584X; 1423-0240; 2296-5262; 2296-5270Online Volltext: dx.doi.org/